
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5102707/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Myositis-specific autoantibodies and QTc changes by ECG in idiopathic inflammatory myopathies. Rheumatology, 2022, 61, 4076-4086.	0.9	4
2	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.5	128
3	The role of environmental exposures and gene–environment interactions in the etiology of systemic lupus erythematous. Journal of Internal Medicine, 2022, 291, 755-778.	2.7	32
4	Lupus anticoagulant in patients with systemic lupus erythematosus is associated with lower E/A ratio and progressive left ventricular dilatation: a five-year follow-up study. European Heart Journal Cardiovascular Imaging, 2022, 23, .	0.5	0
5	Established risk loci for systemic lupus erythematosus at NCF2, STAT4, TNPO3, IRF5 and ITGAM associate with distinct clinical manifestations: A Danish genome-wide association study. Joint Bone Spine, 2022, 89, 105357.	0.8	1
6	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
7	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
8	Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy. Biomedicine and Pharmacotherapy, 2022, 148, 112687.	2.5	3
9	Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Annals of the Rheumatic Diseases, 2022, 81, 1085-1095.	0.5	26
10	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
11	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
12	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.5	31
13	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Annals of the Rheumatic Diseases, 2021, 80, 109-117.	0.5	35
14	Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. PLoS ONE, 2021, 16, e0247256.	1.1	7
15	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
16	Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology, 2021, 60, 5549-5559.	0.9	11
17	Interaction between the <i>STAT4</i> rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 1183-1189.	0.5	10
18	Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study. Lupus Science and Medicine, 2021, 8, e000474.	1.1	7

#	Article	IF	CITATIONS
19	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
20	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
21	OP0289â€LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON MULTINATIONAL MULTICENTER COHORT. Annals of the Rheumatic Diseases, 2021, 80, 177-178.	I- OR) Tj E1 0.5	「Qq1 1 0.784 1
22	Variants in BANK1 are associated with lupus nephritis of European ancestry. Genes and Immunity, 2021, 22, 194-202.	2.2	9
23	Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000507.	1.1	8
24	Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies. Translational Research, 2021, 238, 63-75.	2.2	15
25	Birthweight, body size, and growth during childhood and risks of rheumatoid arthritis: a large Danish cohort study. Scandinavian Journal of Rheumatology, 2021, , 1-9.	0.6	0
26	Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population. Journal of Autoimmunity, 2021, 123, 102692.	3.0	8
27	Microvesicles in active lupus nephritis show Toll-like receptor 9-dependent co-expression of galectin-3 binding protein and double-stranded DNA. Clinical and Experimental Immunology, 2021, 204, 64-77.	1.1	6
28	PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. Frontiers in Immunology, 2021, 12, 707690.	2.2	10
29	Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. Lupus, 2021, 30, 2124-2134.	0.8	3
30	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
31	The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes. Clinical and Experimental Rheumatology, 2021, 39, 1071-1076.	0.4	2
32	Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 1360-1368.	0.4	1
33	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	1.0	34
34	Lymphopenia and neutropenia are associated with subsequent incident proteinuria in Danish patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2020, 49, 122-130.	0.6	6
35	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
36	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23

#	Article	IF	CITATIONS
37	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
38	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
39	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
40	Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. International Journal of Infectious Diseases, 2020, 91, 188-195.	1.5	13
41	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.5	35
42	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatology, The, 2020, 2, e735-e736.	2.2	3
43	P169â€Association between cardiovascular autonomic neuropathy and quality of life in patients with systemic lupus erythematosus. , 2020, , .		0
44	P91â€The development and validation of a polygenic risk score for myocardial infarction in SLE. , 2020, , .		0
45	P90â€Genetic risk, smoking and the development of systemic autoimmune rheumatic disease. , 2020, , .		Ο
46	P105â€Expression diversity of interferon-stimulated genes in peripheral blood cells from patients with systemic lupus erythematosus. , 2020, , .		0
47	O8â€Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
48	P168â€Prevalence and characteristics of cardiovascular autonomic dysfunction in patients with systemic lupus erythematosus. , 2020, , .		1
49	O34â€Variants in <i>BANK1</i> are associated with lupus nephritis. , 2020, , .		0
50	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9
51	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
52	Early life body size, growth and risks of systemic lupus erythematosus – A large Danish observational cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1507-1512.	1.6	3
53	Association between MRI findings and patientâ€reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse. International Journal of Rheumatic Diseases, 2020, 23, 488-498.	0.9	5
54	THU0271â€PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES. Annals of the Rheumatic Diseases, 2020, 79, 362.1-362.	0.5	0

#	Article	IF	CITATIONS
55	FRI0155â€Î ^t MULTICENTER "AT-RISK―COHORT FOR THE DISCOVERY OF ENVIRONMENTAL, CLINICAL AND MOLECULAR PREDICTORS FOR THE TRANSITION INTO SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Annals of the Rheumatic Diseases, 2020, 79, 661.1-661.	0.5	0
56	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
57	Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2019, 48, 1-8.	0.6	19
58	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
59	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
60	Stimulation of Mononuclear Cells Through Toll-Like Receptor 9 Induces Release of Microvesicles Expressing Double-Stranded DNA and Galectin 3-Binding Protein in an Interferon-α-Dependent Manner. Frontiers in Immunology, 2019, 10, 2391.	2.2	5
61	Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study. Journal of the American Heart Association, 2019, 8, e013405.	1.6	59
62	EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls. Antibodies, 2019, 8, 35.	1.2	8
63	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.5	51
64	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	1.0	15
65	Erythrocytes restrict microvesicleâ€induced production of reactive oxygen species by polymorphonuclear leukocytes. Apmis, 2019, 127, 538-542.	0.9	0
66	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
67	The study of interactions between genome and exposome in the development of systemic lupus erythematosus. Autoimmunity Reviews, 2019, 18, 382-392.	2.5	42
68	Increased antibody levels to stage-specific Epstein–Barr virus antigens in systemic autoimmune diseases reveal a common pathology. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 7-16.	0.6	22
69	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
70	AB0652â€QTC INTERVAL PROLONGATION IN A SCANDINAVIAN COHORT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES AND SYSTEMIC SCLEROSIS: CORRELATIONS WITH CLINICAL VARIABLES. , 2019, , .		0
71	FRI0320â€CN-1A AUTOANTIBODIES ARE SPECIFIC FOR SPORADIC INCLUSION BODY MYOSITIS. , 2019, , .		0
72	2613. The Epidemiology of Respiratory Syncytial Virus (RSV) in People with Immune Dysfunction Seen at a Tertiary Hospital Between 2010 and 2017. Open Forum Infectious Diseases, 2019, 6, S908-S909.	0.4	0

#	Article	IF	CITATIONS
73	The effect of a compression bandage on the distribution of radiodense contrast medium after palmar digital nerve blocks. Equine Veterinary Journal, 2019, 51, 261-265.	0.9	2
74	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
75	Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. Rheumatology, 2019, 58, 110-119.	0.9	29
76	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
77	Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis. Scandinavian Journal of Rheumatology, 2019, 48, 133-140.	0.6	25
78	Multifocal vertebral sclerosing bone changes and soft tissue masses caused by Hodgkin's lymphoma in a patient with systemic lupus erythematosus: a case report. Scandinavian Journal of Rheumatology, 2019, 48, 77-78.	0.6	0
79	The existential experience of everyday life with systemic lupus erythematosus. Journal of Advanced Nursing, 2018, 74, 1170-1179.	1.5	11
80	Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis. Scientific Reports, 2018, 8, 3684.	1.6	26
81	Clinical and Serological Associations with the Development of Incident Proteinuria in Danish Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 934-941.	1.0	13
82	Twin <scp>DNA</scp> Methylation Profiling Reveals Flareâ€Dependent Interferon Signature and B Cell Promoter Hypermethylation in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 878-890.	2.9	61
83	Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Scandinavian Journal of Rheumatology, 2018, 47, 259-269.	0.6	10
84	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	1.5	55
85	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.5	50
86	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	0.9	53
87	Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, 1041-1046.	0.9	32
88	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	1.5	26
89	Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. Seminars in Arthritis and Rheumatism, 2018, 47, 538-544.	1.6	42
90	Being in a standstillâ€ofâ€life: women's experience of being diagnosed with systemic lupus erythematosus: a hermeneuticâ€phenomenological study. Scandinavian Journal of Caring Sciences, 2018, 32, 654-662.	1.0	9

#	Article	IF	CITATIONS
91	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
92	The use of synthetic peptides for detection of anti-citrullinated protein antibodies in rheumatoid arthritis. Journal of Immunological Methods, 2018, 454, 6-14.	0.6	15
93	Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatology, 2018, 2, 36.	0.6	31
94	S7D:5â€The diagnostic phase of lupus – being in a standstill-of-life. , 2018, , .		0
95	PS2:39â€Genetic and environmental risk factors for systemic lupus erythematosus – a nationwide population study. , 2018, , .		0
96	S4A:4â€Beta2-microglobulin (b2mg) plasma levels associate with markers of atherosclerosis in patients with systemic lupus erythematosus (sle). , 2018, , .		0
97	PS2:40â€Association of peptidylarginine deiminase (padi)-4 polymorphisms with systemic lupus erythematosus and lupus nephritis. , 2018, , .		Ο
98	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	5.5	6,961
99	Plasma levels of β2-microglobulin are associated with atherosclerosis in patients with systemic lupus erythematosus: a cross-sectional cohort study. Lupus, 2018, 27, 1517-1523.	0.8	7
100	OP0020â \in Validation of new systemic lupus erythematosus classification criteria. , 2018, , .		2
101	Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. Rheumatology, 2018, 57, 1964-1971.	0.9	11
102	Microparticles - culprits in the pathogenesis of systemic lupus erythematosus?. Expert Review of Clinical Immunology, 2018, 14, 443-445.	1.3	8
103	Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. PLoS ONE, 2018, 13, e0193244.	1.1	5
104	SAT0498â€Abnormal electrocardiographic findings in a scandinavian cohort of patients with idiopathic inflammatory myopathies. , 2018, , .		0
105	OP0038â€Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in remission in routine care – 2-year outcomes and identification of predictors. , 2018, , .		0
106	AB0590â€A validation study of the pregnancy morbidity questionnaire(PMQ) in women with antiphospholipid antibodies and pregnancy morbidity. , 2018, , .		0
107	The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study. Rheumatology, 2017, 56, kew475.	0.9	53
108	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.5	268

#	Article	IF	CITATIONS
109	Efficient evaluation of humoral immune responses by the use of serum pools. Journal of Immunological Methods, 2017, 443, 1-8.	0.6	4
110	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	0.8	52
111	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.5	107
112	Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus, 2017, 26, 1072-1081.	0.8	36
113	A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. Clinical Proteomics, 2017, 14, 11.	1.1	26
114	Surface complement C3 fragments and cellular binding of microparticles in patients with SLE. Lupus Science and Medicine, 2017, 4, e000193.	1.1	18
115	Quality of life correlates with muscle strength in patients with dermato- or polymyositis. Clinical Rheumatology, 2017, 36, 2289-2295.	1.0	20
116	HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Seminars in Thrombosis and Hemostasis, 2017, 43, 562-571.	1.5	89
117	Family history of systemic lupus erythematosus and risk of autoimmune disease: Nationwide Cohort Study in Denmark 1977–2013. Rheumatology, 2017, 56, 957-964.	0.9	21
118	Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. Clinical Rheumatology, 2017, 36, 335-341.	1.0	9
119	SAT0045â€11 years' follow-up of a danish 2-year treat-to-target randomized controlled trial in patients with early rheumatoid arthritis: baseline predictors of functional and radiographic outcomes. , 2017, , .		0
120	OP0033â \in SPECT- and PET/CT imaging in newly onset idiopathic inflammatory myopathy. , 2017, , .		0
121	A fluorescence sedimentation assay for dsDNA antibodies. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 465-471.	0.6	3
122	OP0002â€Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus. , 2017, , .		0
123	Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus. Clinical Proteomics, 2017, 14, 23.	1.1	19
124	Breast cancer in systemic lupus. Lupus, 2017, 26, 311-315.	0.8	21
125	The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 570.	0.7	16
126	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	1.6	1

#	Article	IF	CITATIONS
127	Mycobacterium intracellulare Infection Mimicking Progression of Scleroderma. Case Reports in Rheumatology, 2017, 2017, 1-3.	0.2	0
128	Microparticles from patients with systemic lupus erythematosus induce production of reactive oxygen species and degranulation of polymorphonuclear leukocytes. Arthritis Research and Therapy, 2017, 19, 230.	1.6	13
129	Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy. EJNMMI Research, 2017, 7, 97.	1.1	3
130	THU0663â€Serum galectin-3 binding protein is a novel predictor of venous thromboembolism in patients with systemic lupus erythematosus (SLE). , 2017, , .		0
131	Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 50, 443-453.	1.2	210
132	Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients. Journal of Immunology Research, 2016, 2016, 1-16.	0.9	22
133	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	2.9	40
134	Cardiac Abnormalities in Adult Patients With Polymyositis or Dermatomyositis as Assessed by Noninvasive Modalities. Arthritis Care and Research, 2016, 68, 1012-1020.	1.5	51
135	Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. Journal of Rheumatology, 2016, 43, 1335-1339.	1.0	48
136	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science and Medicine, 2016, 3, e000143.	1.1	50
137	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	1.1	51
138	AB0263â€Agreement between Das28, Acr/eular, Sdai, Cdai and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care. Annals of the Rheumatic Diseases, 2016, 75, 989.2-990.	0.5	0
139	Page charges. Scandinavian Journal of Rheumatology, 2016, 45, 438-438.	0.6	0
140	The assessment of serum-mediated phagocytosis of necrotic material by polymorphonuclear leukocytes to diagnose and predict the clinical features of systemic lupus erythematosus: an observational longitudinal study. Arthritis Research and Therapy, 2016, 18, 44.	1.6	5
141	Humoral markers of active Epstein–Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus. Lupus, 2016, 25, 1567-1576.	0.8	9
142	Application of synthetic peptides for detection of anti-citrullinated peptide antibodies. Peptides, 2016, 76, 87-95.	1.2	13
143	"Kill―the messenger: Targeting of cell-derived microparticles in lupus nephritis. Autoimmunity Reviews, 2016, 15, 719-725.	2.5	22
144	Traditional Cardiovascular Risk Factors and Coronary Artery Calcification in Adults With Polymyositis and Dermatomyositis: A Danish Multicenter Study. Arthritis Care and Research, 2015, 67, 848-854.	1.5	38

#	Article	IF	CITATIONS
145	Isotypes of Epstein-Barr Virus Antibodies in Rheumatoid Arthritis: Association with Rheumatoid Factors and Citrulline-Dependent Antibodies. BioMed Research International, 2015, 2015, 1-9.	0.9	21
146	Scandinavian Journal of Rheumatology: reporting international research with a scent of Scandinavian science. Scandinavian Journal of Rheumatology, 2015, 44, 1-1.	0.6	6
147	Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. Lupus, 2015, 24, 1150-1160.	0.8	50
148	O5-04-06: Moderate to high-intensity physical exercise in patients with Alzheimer's disease. , 2015, 11, P324-P325.		2
149	Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 8-12.	0.6	22
150	Ultrasonographic abnormalities and inter-reader reliability in Danish patients with systemic lupus erythematosus – a comparison with clinical examination of wrist and metacarpophalangeal joints. Lupus, 2015, 24, 712-719.	0.8	24
151	Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scandinavian Journal of Rheumatology, 2015, 44, 143-149.	0.6	49
152	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
153	Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis. BMC Musculoskeletal Disorders, 2015, 16, 191.	0.8	22
154	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2015, 74, 1011-1018.	0.5	610
155	Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus. Molecular Immunology, 2015, 63, 209-214.	1.0	34
156	The Circulating Cell-free microRNA Profile in Systemic Sclerosis Is Distinct from Both Healthy Controls and Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 214-221.	1.0	47
157	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	0.8	106
158	Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies. PLoS ONE, 2015, 10, e0138753.	1.1	27
159	Cardiac abnormalities assessed by non-invasive techniques in patients with newly diagnosed idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2015, 33, 706-14.	0.4	19
160	Infections Increase Risk of Arterial and Venous Thromboses in Danish Patients with Systemic Lupus Erythematosus: 5102 Patient-years of Followup. Journal of Rheumatology, 2014, 41, 1817-1822.	1.0	6
161	Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study. Lupus Science and Medicine, 2014, 1, e000007.	1.1	28
162	Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2014, 1, e000026.	1.1	34

#	Article	IF	CITATIONS
163	Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunology, Immunotherapy, 2014, 63, 1341-1346.	2.0	55
164	MBL2 gene variants coding for mannose-binding lectin deficiency are associated with increased risk of nephritis in Danish patients with systemic lupus erythematosus. Lupus, 2014, 23, 1105-1111.	0.8	15
165	Low prevalence of positive skin pathergy testing in Danish patients with Behçet's disease. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 259-260.	1.3	4
166	Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenetics and Genomics, 2014, 24, 401-405.	0.7	38
167	Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression. Scandinavian Journal of Rheumatology, 2014, 43, 91-100.	0.6	19
168	Smoking and polymorphisms of genes encoding mannose-binding lectin and surfactant protein-D in patients with rheumatoid arthritis. Rheumatology International, 2014, 34, 373-380.	1.5	11
169	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.5	115
170	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.5	558
171	Increased risk of rheumatoid arthritis in women with pregnancy complications and poor self-rated health: a study within the Danish National Birth Cohort. Rheumatology, 2014, 53, 1513-1519.	0.9	19
172	Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes. Rheumatology International, 2014, 34, 1401-1408.	1.5	28
173	Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus. Molecular Biology Reports, 2014, 41, 5755-5763.	1.0	54
174	Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Annals of the Rheumatic Diseases, 2014, 73, 1515-1521.	0.5	89
175	Reduced response to Epstein–Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Science and Medicine, 2014, 1, e000015.	1.1	41
176	Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatology International, 2013, 33, 529-533.	1.5	14
177	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	3.0	249
178	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
179	Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5Âyears of duration. Rheumatology International, 2013, 33, 2763-2772.	1.5	1
180	Breast Cancer in Systemic Lupus Erythematosus. Oncology, 2013, 85, 117-121.	0.9	24

#	Article	IF	CITATIONS
181	Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients. Modern Rheumatology, 2013, 23, 729-740.	0.9	6
182	A heparin-based method for flow cytometric analysis of microparticles directly from platelet-poor plasma in calcium containing buffer. Journal of Immunological Methods, 2013, 388, 49-59.	0.6	22
183	Impact of the Tumor Necrosis Factor Receptor-Associated Protein 1 (Trap1) on Renal DNasel Shutdown and on Progression of Murine and Human Lupus Nephritis. American Journal of Pathology, 2013, 182, 688-700.	1.9	23
184	Circulating MicroRNA Expression Profiles Associated With Systemic Lupus Erythematosus. Arthritis and Rheumatism, 2013, 65, 1324-1334.	6.7	217
185	Unique Protein Signature of Circulating Microparticles in Systemic Lupus Erythematosus. Arthritis and Rheumatism, 2013, 65, 2680-2690.	6.7	97
186	Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scandinavian Journal of Rheumatology, 2013, 42, 311-316.	0.6	27
187	Circulating microparticles and plasma levels of soluble E- and P-selectins in patients with systemic sclerosis. Scandinavian Journal of Rheumatology, 2013, 42, 473-482.	0.6	26
188	THU0239â€Cardiovascular risk factors in adults with polymyositis and dermatomyositis – a multicenter study. Annals of the Rheumatic Diseases, 2013, 71, 236.1-236.	0.5	0
189	FRIO115â€Non-steroidal anti-inflammatory drug use and the risk of cardiovascular disease in patients with rheumatoid arthritis – is there a risk?:. Annals of the Rheumatic Diseases, 2013, 71, 349.1-349.	0.5	14
190	Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients. Modern Rheumatology, 2013, 23, 729-740.	0.9	11
191	Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus, 2012, 21, 1098-1104.	0.8	34
192	Combination of Autoantibodies Against Different Histone Proteins Influences Complement-dependent Phagocytosis of Necrotic Cell Material by Polymorphonuclear Leukocytes in Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 1619-1627.	1.0	21
193	IgG Glycosylation Changes and <i>MBL2</i> Polymorphisms: Associations with Markers of Systemic Inflammation and Joint Destruction in Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 463-469.	1.0	36
194	Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Annals of the Rheumatic Diseases, 2012, 71, 851-856.	0.5	70
195	Quantitative Proteome Profiling of Normal Human Circulating Microparticles. Journal of Proteome Research, 2012, 11, 2154-2163.	1.8	56
196	Nonlymphoma hematological malignancies in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, .	1.6	0
197	Epstein–Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scandinavian Journal of Rheumatology, 2012, 41, 280-289.	0.6	44
198	Raffinose family oligosaccharide utilisation by probiotic bacteria: insight into substrate recognition, molecular architecture and diversity of GH36 α-galactosidases. Biocatalysis and Biotransformation, 2012, 30, 316-325.	1.1	15

#	Article	IF	CITATIONS
199	Childbirths and risk of female predominant and other autoimmune diseases in a population-based Danish cohort. Journal of Autoimmunity, 2012, 38, J81-J87.	3.0	56
200	Hyperemesis, gestational hypertensive disorders, pregnancy losses and risk of autoimmune diseases in a Danish population-based cohort. Journal of Autoimmunity, 2012, 38, J120-J128.	3.0	30
201	Silencing of Renal DNasel in Murine Lupus Nephritis Imposes Exposure of Large Chromatin Fragments and Activation of Toll Like Receptors and the Clec4e. PLoS ONE, 2012, 7, e34080.	1.1	21
202	Increased IgG on cellâ€derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis and Rheumatism, 2012, 64, 1227-1236.	6.7	154
203	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
204	Specificity of anti-histone antibodies determines complement-dependent phagocytosis of necrotic material by polymorphonuclear leukocytes in the presence of serum from patients with SLE. The LE cell phenomenon revisited. Molecular Immunology, 2011, 48, 1688.	1.0	0
205	Socio-demographic factors, reproductive history and risk of osteoarthritis in a cohort of 4.6 million Danish women and men. Osteoarthritis and Cartilage, 2011, 19, 1176-1182.	0.6	41
206	Serum cysteine proteases and their inhibitors in rheumatoid arthritis: relation to disease activity and radiographic progression. Clinical Rheumatology, 2011, 30, 633-638.	1.0	4
207	Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus. Immunology Letters, 2011, 138, 179-186.	1.1	14
208	High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: A long-term followup study in a Danish cohort. Arthritis and Rheumatism, 2011, 63, 3032-3037.	6.7	108
209	Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis and Rheumatism, 2011, 63, 3067-3077.	6.7	110
210	Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 1563-1568.	1.0	14
211	Do subjective cognitive complaints correlate with cognitive impairment in systemic lupus erythematosus? A Danish outpatient study. Lupus, 2011, 20, 35-43.	0.8	42
212	High Risk of Ischemic Heart Disease in Patients with Lupus Nephritis. Journal of Rheumatology, 2011, 38, 2400-2405.	1.0	34
213	Longâ€ŧerm mortality and renal outcome in a cohort of 100 patients with Lupus Nephritis. Arthritis Care and Research, 2010, 62, 873-880.	1.5	170
214	Mortality and Predictors of Mortality in Rheumatoid Arthritis — A Role for Mannose-binding Lectin?. Journal of Rheumatology, 2010, 37, 536-543.	1.0	26
215	National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia?. Annals of the Rheumatic Diseases, 2010, 69, 358-363.	0.5	50
216	Uncoupling of Collagen II Metabolism in Newly Diagnosed, Untreated Rheumatoid Arthritis Is Linked to Inflammation and Antibodies Against Cyclic Citrullinated Peptides. Journal of Rheumatology, 2010, 37, 1113-1120.	1.0	13

#	Article	IF	CITATIONS
217	Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Annals of the Rheumatic Diseases, 2010, 69, 1789-1795.	0.5	168
218	Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1815-1821.	1.0	15
219	Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 395-405.	0.9	127
220	Double role of mannose-binding lectin in relation to carotid intima–media thickness in patients with rheumatoid arthritis. Molecular Immunology, 2010, 47, 713-718.	1.0	32
221	Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R39.	1.6	19
222	Renal cell apoptosis in human lupus nephritis: a histological study. Lupus, 2009, 18, 994-999.	0.8	11
223	MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Annals of the Rheumatic Diseases, 2009, 68, 384-390.	0.5	335
224	Comparison of Screening Procedures for <i>Mycobacterium tuberculosis</i> Infection Among Patients with Inflammatory Diseases. Journal of Rheumatology, 2009, 36, 1876-1884.	1.0	47
225	High-resolution MRI for assessment of middle meningeal artery involvement in giant cell arteritis. Annals of the Rheumatic Diseases, 2009, 68, 1369-1370.	0.5	12
226	Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case–control studies. Annals of the Rheumatic Diseases, 2009, 68, 222-227.	0.5	166
227	Serum Levels of Ficolin-3 (Hakata Antigen) in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 757-759.	1.0	47
228	Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study. Clinical Pharmacology and Therapeutics, 2009, 85, 190-197.	2.3	158
229	Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56. Journal of Investigative Dermatology, 2009, 129, 1992-1999.	0.3	6
230	Mannose-Binding Lectin Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-Cyclic Citrullinated Peptide-Positive Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 731-735.	1.0	19
231	Circulating chromatin–anti-chromatin antibody complexes bind with high affinity to dermo-epidermal structures in murine and human lupus nephritis. Lupus, 2009, 18, 597-607.	0.8	36
232	Serum levels of mannose binding lectin are associated with carotid intima-media thickness in patients with rheumatoid arthritis. Molecular Immunology, 2009, 46, 2870.	1.0	0
233	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2009, 68, 1428-1432.	0.5	262
234	Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis. Clinical Rheumatology, 2008, 27, 1053-1056.	1.0	5

#	Article	IF	CITATIONS
235	The pattern of use of nonâ€steroidal antiâ€inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiology and Drug Safety, 2008, 17, 822-833.	0.9	122
236	Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factorâ€kappa B ligand, and highâ€sensitivity Câ€reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scandinavian Journal of Rheumatology, 2008, 37, 241-247.	0.6	42
237	The renal metallothionein expression profile is altered in human lupus nephritis. Arthritis Research and Therapy, 2008, 10, R76.	1.6	6
238	22Cancer immunity and autoimmunity; two sides of the same coin (?). Apmis, 2008, 116, 416-416.	0.9	0
239	A new radiological index for assessing asphericity of the femoral head in cam impingement. Journal of Bone and Joint Surgery: British Volume, 2007, 89-B, 1309-1316.	3.4	179
240	Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and highâ€sensitivity Câ€reactive protein. Scandinavian Journal of Clinical and Laboratory Investigation, 2007, 67, 821-835.	0.6	31
241	Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 21-29.	6.7	55
242	Strong combined gene–environment effects in anti–cyclic citrullinated peptide–positive rheumatoid arthritis: A nationwide case–control study in Denmark. Arthritis and Rheumatism, 2007, 56, 1446-1453.	6.7	180
243	Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Research and Therapy, 2006, 8, R133.	1.6	299
244	Conventional radiography requires a MRI-estimated bone volume loss of 20% to 30% to allow certain detection of bone erosions in rheumatoid arthritis metacarpophalangeal joints. Arthritis Research and Therapy, 2006, 8, R59.	1.6	34
245	High resolution 100kV electron beam lithography in SU-8. Microelectronic Engineering, 2006, 83, 1609-1612.	1.1	83
246	Osteoarthritis of the first carpometacarpal joint: a study of radiology and clinical epidemiology. Osteoarthritis and Cartilage, 2006, 14, 496-500.	0.6	56
247	Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology, 2006, 45, 833-841.	0.9	45
248	Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation, 2006, 113, 2906-2913.	1.6	399
249	Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study. Journal of Rheumatology, 2006, 33, 1069-74.	1.0	57
250	Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. Journal of Rheumatology, 2006, 33, 1563-9.	1.0	160
251	The smallest detectable difference and sensitivity to change or magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: A comparison of the omeract rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the sharp/van der heijde radiographic score. Arthritis and	6.7	115
252	Rheumatism, 2005, 52, 2300-2306. Joint space width in dysplasia of the hip. Journal of Bone and Joint Surgery: British Volume, 2005, 87-B, 471-477.	3.4	41

#	Article	IF	CITATIONS
253	Technology for Fabrication of Nanostructures by Standard Cleanroom Processing and Nanoimprint Lithography. Japanese Journal of Applied Physics, 2005, 44, 5606-5608.	0.8	10
254	Absence of highâ€affinity calreticulin autoantibodies in patients with systemic rheumatic diseases and coeliac disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 403-412.	0.6	12
255	High serum levels of YKLâ€40 in patients with systemic sclerosis are associated with pulmonary involvement. Scandinavian Journal of Rheumatology, 2005, 34, 293-297.	0.6	71
256	Optimised, low cost, low field dedicated extremity MRI is highly specific and sensitive for synovitis and bone erosions in rheumatoid arthritis wrist and finger joints: comparison with conventional high field MRI and radiography. Annals of the Rheumatic Diseases, 2005, 64, 1280-1287.	0.5	141
257	Mannose-Binding Lectin Variant Alleles and the Risk of Arterial Thrombosis in Systemic Lupus Erythematosus. New England Journal of Medicine, 2004, 351, 260-267.	13.9	182
258	Detection of Antinuclear Antibodies by Solid-Phase Immunoassays and Immunofluorescence Analysis. Clinical Chemistry, 2004, 50, 2141-2147.	1.5	72
259	Factors influencing hip joint space in asymptomatic subjects. Osteoarthritis and Cartilage, 2004, 12, 698-703.	0.6	23
260	Young age of onset is associated with increased prevalence of circulating IgM rheumatoid factor and antinuclear antibodies at presentation in women with rheumatoid arthritis. Clinical Rheumatology, 2004, 23, 121-122.	1.0	8
261	Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. European Journal of Epidemiology, 2004, 19, 1097-1103.	2.5	78
262	Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 1097-1106.	6.7	151
263	Diagnostic classification of non-specific low back pain. A new system integrating patho-anatomic and clinical categories. Physiotherapy Theory and Practice, 2003, 19, 213-237.	0.6	12
264	Association of b2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus, 2001, 10, 533-538.	0.8	17
265	The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. TIRA Group. Journal of Rheumatology, 2001, 28, 935-42.	1.0	47
266	Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. Journal of Rheumatology, 2001, 28, 2454-9.	1.0	71
267	Ultrasonic Measurement of Skin Thickness in Patients with Systemic Sclerosis. Acta Dermato-Venereologica, 2000, 80, 59-60.	0.6	18
268	Comparative Evaluation of Low-Molecular-Mass Proteins from <i>Mycobacterium tuberculosis</i> Identifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens. Infection and Immunity, 2000, 68, 214-220.	1.0	267
269	Determination of autoantibodies to annexin XI in systemic autoimmune diseases. Lupus, 2000, 9, 515-520.	0.8	30
270	Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 2145-2152.	6.7	199

#	Article	IF	CITATIONS
271	Mortality and Causes of Death of 513 Danish Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Rheumatology, 1999, 28, 75-80.	0.6	128
272	Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scandinavian Journal of Rheumatology, 1999, 28, 288-299.	0.6	34
273	A NARRATIVE REVIEW ON CLASSIFICATION OF PAIN CONDITIONS OF THE UPPER EXTREMITIES. Journal of Rehabilitation Medicine, 1999, 31, 153-164.	1.1	21
274	A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clinical Rheumatology, 1998, 17, 468-477.	1.0	143
275	A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clinical Rheumatology, 1998, 17, 478-484.	1.0	100
276	Physical biodynamics and performance capacities of muscle in patients with fibromyalgia syndrome. Zeitschrift Fur Rheumatologie, 1998, 57, S43-S46.	0.5	5
277	Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Rheumatology, 1998, 37, 750-755.	0.9	125
278	Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Rheumatology, 1998, 37, 39-45.	0.9	88
279	Double-blind, Placebo-controlled Cross-over Study of Intravenous S-Adenosyl-L-Methionine in Patients with Fibromyalgia. Scandinavian Journal of Rheumatology, 1997, 26, 206-211.	0.6	58
280	Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA). Clinical and Experimental Immunology, 1997, 110, 250-256.	1.1	25
281	A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clinical Rheumatology, 1997, 16, 384-390.	1.0	40
282	Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism: Clinical and Experimental, 1995, 44, 1570-1576.	1.5	69
283	A controlled study on serum insulin-like growth factor-I and urinary excretion of growth hormone in fibromyalgia. Journal of Rheumatology, 1995, 22, 1138-40.	1.0	26
284	Muscle function and origin of pain in fibromyalgia. Bailliere's Clinical Rheumatology, 1994, 8, 721-746.	1.0	25
285	Chronic widespread musculoskeletal pain–the fibromyalgia syndrome. Danish Medical Bulletin, 1994, 41, 541-64.	0.1	1
286	A Four-year Follow-up Study in fibromyalgia. Relationship to Chronic Fatigue Syndrome. Scandinavian Journal of Rheumatology, 1993, 22, 35-38.	0.6	58
287	Fibromyalgia in the Adutt Danish Population: II. A Study of Clinical Features. Scandinavian Journal of Rheumatology, 1993, 22, 238-242.	0.6	33
288	Preliminary Results of a 4-Year Follow-Up Study in Fibromyalgia. Journal of Musculoskeletal Pain, 1993, 1, 159-163.	0.3	1

#	Article	IF	CITATIONS
289	Preliminary Communication on the Prevalence of Fibromyalgia in the Adult Danish Population. Journal of Musculoskeletal Pain, 1993, 1, 153-157.	0.3	Ο
290	Fibromyalgia in the Adult Danish Population: I. A Prevalence Study. Scandinavian Journal of Rheumatology, 1993, 22, 233-237.	0.6	92
291	Clinical Features in Patients with Chronic Muscle Pain — with Special Reference to Fibromyalgia. Scandinavian Journal of Rheumatology, 1993, 22, 69-76.	0.6	35
292	Tissue specificity and induction of class I, II and III chitinases in barley (Hordeum vulgare). Physiologia Plantarum, 1993, 89, 490-498.	2.6	2
293	Bone mass and turnover in fibromyalgia. Journal of Rheumatology, 1993, 20, 856-9.	1.0	7
294	The Prevalence of Fibromyalgia and Widespread Chronic Musculoskeletal Pain in the General Population. Scandinavian Journal of Rheumatology, 1992, 21, 261-262.	0.6	17
295	Muscle strength and endurance compared to aerobic capacity in primary fibromyalgia syndrome. Clinical and Experimental Rheumatology, 1992, 10, 419-20.	0.4	9
296	31P magnetic resonance spectroscopy of skeletal muscle in patients with fibromyalgia. Journal of Rheumatology, 1992, 19, 1600-3.	1.0	38
297	Dynamic muscular endurance in primary fibromyalgia compared with chronic myofascial pain syndrome. Archives of Physical Medicine and Rehabilitation, 1992, 73, 170-3.	0.5	28
298	Oral S-adenosylmethionine in Primary Fibromyalgia. Double-blind Clinical Evaluation. Scandinavian Journal of Rheumatology, 1991, 20, 294-302.	0.6	128
299	Single Cell Morphology of Muscle in Patients with Chronic Muscle Pain. Scandinavian Journal of Rheumatology, 1991, 20, 336-343.	0.6	48
300	Isokinetic and isometric muscle strength combined with transcutaneous electrical muscle stimulation in primary fibromyalgia syndrome. Journal of Rheumatology, 1991, 18, 1390-3.	1.0	66
301	Screening for autoantibodies in patients with primary fibromyalgia syndrome and a matched control group. Apmis, 1990, 98, 655-658.	0.9	13
302	PRIMARY FIBROMYALGIA: CLINICAL PARAMETERS IN RELATION TO SERUM PROCOLLAGEN TYPE III AMINOTERMINAL PEPTIDE. Rheumatology, 1990, 29, 174-177.	0.9	19
303	Characterization of two antifungal endochitinases from barley grain. Physiologia Plantarum, 1990, 79, 554-562.	2.6	41
304	Inter-relations between clinical parameters and muscle function in patients with primary fibromyalgia. Clinical and Experimental Rheumatology, 1989, 7, 493-8.	0.4	19
305	Patients with polymyositis show changes in muscle protein charges. Journal of Rheumatology, 1989, 16, 1542-4.	1.0	2
306	Isometric and isokinetic muscle strength in patients with fibrositis syndrome. New characteristics for a difficult definable category of patients. Scandinavian Journal of Rheumatology, 1987, 16, 61-5.	0.6	44